Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
Adult
Biological Transport
/ drug effects
Exenatide
/ metabolism
Female
Gelatin
/ pharmacology
Humans
Image Processing, Computer-Assisted
Indium Radioisotopes
/ therapeutic use
Insulinoma
/ diagnostic imaging
Isotope Labeling
Kidney
/ drug effects
Male
Single Photon Emission Computed Tomography Computed Tomography
Succinates
/ pharmacology
dosimetry
exendin-4
insulinoma
kidney uptake
radionuclide therapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
06
09
2018
accepted:
26
10
2018
pubmed:
7
12
2018
medline:
31
3
2020
entrez:
4
12
2018
Statut:
ppublish
Résumé
Being highly expressed in insulinomas, the glucagonlike peptide-1 receptor (GLP-1R) is a potential target for diagnosis, localization, and treatment with the radiolabeled GLP-1R agonist exendin. Tracer accumulation in the kidneys, however, hampers accurate diagnostic visualization of pancreatic tissue and prohibits the therapeutic application of radiolabeled exendin for β-cell-derived tumors. Therefore, we evaluated the ability of succinylated gelatin (Gelofusine) to reduce the renal accumulation of radiolabeled exendin in humans, and we performed dosimetric calculations to estimate the maximum absorbed insulinoma dose that could be achieved if exendin were to be used for peptide receptor radionuclide therapy.
Identifiants
pubmed: 30504139
pii: jnumed.118.219980
doi: 10.2967/jnumed.118.219980
doi:
Substances chimiques
Indium Radioisotopes
0
Succinates
0
succinylated gelatin
39340-57-3
Gelatin
9000-70-8
Exenatide
9P1872D4OL
Indium-111
E9NGC49E0T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-816Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.